Hou Jing-Yi, Xu He, Cao Guang-Zhao, Tian Liang-Liang, Wang Li-Han, Zhu Nai-Qiang, Zhang Jing-Jing, Yang Hong-Jun
Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Robot Intelligent Laboratory of Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences and MEGAROBO, Beijing, China.
Front Pharmacol. 2023 Apr 10;14:1175970. doi: 10.3389/fphar.2023.1175970. eCollection 2023.
Dengzhan Shengmai (DZSM), a traditional Chinese medicine formulation, has been administered extensively to elderly individuals with cognitive impairment (CI). However, the underlying mechanisms by which Dengzhan Shengmai improves cognitive impairment remains unknown. This study aimed to elucidate the underlying mechanism of the effect of Dengzhan Shengmai on aging-associated cognitive impairment a comprehensive combination of transcriptomics and microbiota assessment. Dengzhan Shengmai was orally administered to a D-galactose-induced aging mouse model, and evaluation with an open field task (OFT), Morris water maze (MWM), and histopathological staining was performed. Transcriptomics and 16S rDNA sequencing were applied to elucidate the mechanism of Dengzhan Shengmai in alleviating cognitive deficits, and enzyme-linked immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (PCR), and immunofluorescence were employed to verify the results. The results first confirmed the therapeutic effects of Dengzhan Shengmai against cognitive defects; specifically, Dengzhan Shengmai improved learning and impairment, suppressed neuro loss, and increased Nissl body morphology repair. Comprehensive integrated transcriptomics and microbiota analysis indicated that chemokine CXC motif receptor 4 (CXCR4) and its ligand CXC chemokine ligand 12 (CXCL12) were targets for improving cognitive impairments with Dengzhan Shengmai and also indirectly suppressed the intestinal flora composition. Furthermore, results confirmed that Dengzhan Shengmai suppressed the expression of CXC motif receptor 4, CXC chemokine ligand 12, and inflammatory cytokines. This suggested that Dengzhan Shengmai inhibited CXC chemokine ligand 12/CXC motif receptor 4 expression and modulated intestinal microbiome composition by influencing inflammatory factors. Thus, Dengzhan Shengmai improves aging-related cognitive impairment effects decreased CXC chemokine ligand 12/CXC motif receptor 4 and inflammatory factor modulation to improve gut microbiota composition.
灯盏生脉(DZSM)是一种中药制剂,已被广泛应用于患有认知障碍(CI)的老年人。然而,灯盏生脉改善认知障碍的潜在机制尚不清楚。本研究旨在通过转录组学和微生物群评估的综合结合,阐明灯盏生脉对衰老相关认知障碍影响的潜在机制。将灯盏生脉口服给予D-半乳糖诱导的衰老小鼠模型,并进行旷场试验(OFT)、莫里斯水迷宫(MWM)和组织病理学染色评估。应用转录组学和16S rDNA测序来阐明灯盏生脉减轻认知缺陷的机制,并采用酶联免疫吸附测定(ELISA)、定量实时聚合酶链反应(PCR)和免疫荧光来验证结果。结果首先证实了灯盏生脉对认知缺陷的治疗作用;具体而言,灯盏生脉改善了学习和损伤,抑制了神经损失,并增加了尼氏体形态修复。综合转录组学和微生物群分析表明,趋化因子CXC基序受体4(CXCR4)及其配体CXC趋化因子配体12(CXCL12)是灯盏生脉改善认知障碍的靶点,并且还间接抑制了肠道菌群组成。此外,结果证实灯盏生脉抑制了CXC基序受体4、CXC趋化因子配体12和炎性细胞因子的表达。这表明灯盏生脉通过影响炎性因子抑制CXC趋化因子配体12/CXC基序受体4的表达并调节肠道微生物群组成。因此,灯盏生脉通过降低CXC趋化因子配体12/CXC基序受体4和调节炎性因子来改善肠道微生物群组成,从而改善与衰老相关的认知障碍。